The AstraZeneca and GSK share prices look like buys to me as the FTSE 100 crashes

Harvey Jones says AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK) have the antidote to the current FTSE 100 (INDEXFTSE: UKX) gloom.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 may have fallen more than 12% in 2018 but not every sector took a pasting. Healthcare swung back into favour as nervy investors started to see the charm in traditional defensive stocks once more.

In rude health

This is quite a shift, as defensives have been out of favour for years now, with investors piling into growth heroes such as US tech giants to take advantage of the longest bull market run in history. Now that run may be coming to an end, and priorities are changing.

FTSE 100 pharma giants AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) both had excellent years, share price wise, rising 17.5% and 13.83%, respectively. Given the carnage elsewhere, that’s more than solid. In fact, it’s a triumph.

With the two stocks currently yielding 3.49% and 5.42%, the total investor return has been even higher. It’s always good to see old friends swing back into favour.

Pharm life

As my Foolish colleague Rupert Hargreaves has pointed out, AstraZeneca has come a long way since management rejected a £69.4bn bid from US drugs giant Pfizer in 2014. Over five years it’s up 63%, an increase that looks even more impressive when you compare it to the 1.5% drop across the FTSE 100 as a whole.

Also, Astra was supposed to be a case of jam tomorrow, as we waited for CEO Pascal Soriot to re-stock its all-important drugs pipeline, to offset the anticipated drop in blockbusters such as blood pressure drug Crestor. Instead, we have jam today. Targets now include delivering Brilinta/Brilique’s potential as a cardiovascular medicine, building its diabetes and respiratory portfolios, delivering six new cancer medicines by 2020, and accelerating growth in emerging markets and Japan.

Consumer giant

After years of negligible or negative earnings growth, City analysts are predicting a 10% increase in 2019. The downside of Astra’s recent successes is that the stock is no longer cheap, trading at a forecast valuation of 21.1 times earnings. It still looks a great long-term buy and hold, though. Especially amid current volatility.

Glaxo’s share price has been far bumpier, actually trading 7% lower than five years ago. It enjoyed a major boost just before Christmas, though, after announcing it has reached an agreement with Pfizer to combine their consumer health businesses into a new ‘world-leading’ joint venture that will have combined sales of nearly £10bn.

Defensive solidity

The group has also been on the acquisition trail, agreeing to buy US-based oncology-focused pharmaceutical group Tesaro Inc for around £4bn. Like Astra, it also has to rebuild its drug pipeline as blockbusters such as lung drug Advair come off patent although, happily, no generic rival to that US money-spinner has popped up yet.

Glaxo offers a more generous yield than Astra and management recently confirmed it plans to pay dividends of 80p per share both this year and next. Earnings are forecast to fall 1% this year, which is disappointing, but the valuation is more attractive than Astra’s. Trading at a forecast 13.1 times earnings, Glaxo looks the ideal buy for these uncertain times.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

harveyj has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Investing Articles

This 10.6% yielder beats every dividend share on the FTSE 100. Can it last?

Harvey Jones couldn't resist the double-digit yield on offer from this FTSE 100 stock. Now he'd like to get some…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

With the FTSE 100 flying, I love the look of this company

The FTSE 100 index has been in rally mode over the last few months, but I think one of it's…

Read more »

Investing Articles

17% of my Stocks and Shares ISA is invested in these 2 UK shares

Stephen Wright looks to focus on investments in companies that have strong competitive advantages. And two UK shares stand out…

Read more »

Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA into Lloyds shares

Harvey Jones bought Lloyds shares last year and is kicking himself for failing to buy even more of them. The…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Apple is still my favourite company in the S&P 500, here’s why

Apple recently unveiled a lot of new software at a developer conference. Here's why the tech giant is still my…

Read more »

Investing Articles

5 great value UK companies I’d buy in a Stocks and Shares ISA and aim to hold for decades 

Harvey Jones is getting to work on his Stocks and Shares ISA. He thinks these five firms have solid income…

Read more »

Value Shares

Are GSK shares a bargain after falling 11%?

GSK shares have taken a hit in recent weeks due to Zantac uncertainty. Here, Edward Sheldon looks at whether they’re…

Read more »

Investing Articles

Nearing £5, could the Rolls-Royce share price hit £6?

The Rolls-Royce share price has soared in the past year. Our writer thinks there could be a strong runway ahead…

Read more »